Enric Monreal

Rituximab and ocrelizumab are two antibodies with a similar mechanism of action that are used in the treatment of multiple sclerosis. Although the former had not shown benefits in primary progressive multiple sclerosis — which affects between 10% and 15% of patients — the latter is approved for this form of the disease. Now, a study conducted in France with more than 1,000 patients has found no benefits with either treatment, as they did not slow the progression of disability in these individuals. The results are published in the journal Neurology.

Researchers have found specific antibodies in the blood of patients years before they showed symptoms of multiple sclerosis. This group of antibodies was present in 10% of the 250 people who later developed the disease, and were part of a sample of over 10 million US military personnel. The finding could have potential for early detection of multiple sclerosis, says the research team in a paper published in Nature Medicine.